The concept that some forms of proteinuria may be induced by the action of circulating systemic permeability factors on the glomerular capillary wall is intriguing. First proposed in the 1970s in the context of steroid-sensitive nephrotic syndrome, the immune system was proposed as a source of such a vascular permeability factor (VPF). More recently, some forms of focal segmental glomerular sclerosis appear to be associated with another type of systemic factor. This paper reviews the evidence for such factors and compares the properties of a number of candidate VPFs.
Introduction
Significant proteinuria is a common feature of both steroid sensitive-nephrotic syndrome (SSNS) and focal segmental glomerulosclerosis (FSGS). Diagnosis rests on the combination of clinical presentation, response to steroids and biopsy findings (in adults). The pathogenesis of these disorders remains elusive. Research into the mechanisms of proteinuria in both conditions has focused on the role of circulating factors able to alter vascular permeability and, therefore, potentially modulate proteinuria. This paper reviews the evidence for vascular permeability factors (VPF) being important in the pathogenesis of SSNS and FSGS.
Steroid-sensitive nephrotic syndrome
The clinical response to immunosuppressive therapy of SSNS patients in relapse provides intriguing, indirect evidence of a link between the immune system and the mechanism of selective proteinuria associated with this disorder [1] . The lack of classic immune inflammation within the kidney, a hallmark of the biopsy pathology, implies (but importantly does not prove) that the causative agent of proteinuria originates outside the kidney itself, either derived from lymphoid tissue or from lymphocytes in passage from blood to lymph. Several VPFs have been described over the last 25 years but what is their relevance and importance to the understanding of SSNS?
The clinical association between SSNS and malignancy (predominantly lymphomatous Hodgkin's disease but also reported for carcinomas [1] ) would lend support to the idea that these tumours secrete a factor that could induce proteinuria. Two rare situations support the concept that the kidney displaying SSNS might be the innocent bystander in a hostile environment. First, the recurrence of SSNS post-transplantation [2] and secondly, the transplantation of two kidneys from a nephrotic donor with SSNS into hosts not suffering nephrosis as their primary disease, with resolution of proteinuria over 6 weeks [3] . This question as to whether the vascular permeability defect is systemic, affecting many vascular beds including the kidney or a specific localized kidney vascular defect, is conceptually important to the understanding of the pathophysiology of SSNS and yet remains unanswered.
I suggest that the experimental data relating to VPF in SSNS should be assessed against the following parameters: VPF should demonstrate:
(i) induction of proteinuria in kidney perfusion experiments; (ii) modulation of the charge barrier within the glomerular capillary wall (GCW);
(iii) temporal bioactivity concordant with disease remission and relapse; (iv) specificity of expression in SSNS compared with other renal diseases; (v) modulation of production or action by steroids (and/or other immunosuppressives).
Isolation and characterization of VPFs from lymphocytes or plasma
The concept of an immune-derived VPF operating in SSNS is attributed to Shaloub [4] . However, it was Lagrue et al. [5, 6] building on work by Pick et al. [7] who demonstrated the existence of a factor that could modulate vascular permeability. This VPF is characteristically produced in vitro by concanavalin A (con A) stimulation of isolated blood mononuclear cells and is defined by a bioassay, which measures the degree of extravasation of systemically injected blue dye in guinea pig skin. This group identified skin VPF as a T lymphocyte product [8] Unfortunately, there has been no convincing proof from parallel experiments that this same VPF, detected by the skin bioassay, has the ability to induce proteinuria or modulate the charge structures within the GCW, although these bioactivities are present in supernatants from temporally separate experiments [12, 17] . There is limited evidence that the bioactivity is more prominent during relapse [10] . It is not specific to SSNS but common in patients with other glomerulopathies [5, 12, 18] . A summary of the properties of VPFs isolated using different assays is shown in Table 1 .
Lymphocyte-derived VPF (following con A stimulation in vitro) has been specifically evaluated for its ability to affect the glomerular charge barrier assessed by colloidal iron staining following in vitro incubation on kidney cryostat sections [19, 20] . Cells from 15 of 17 SSNS patients compared with four of 14 other renal glomerulopathies and three of 18 normal control cells demonstrated the ability to reduce the charge barrier components. Others have demonstrated that con Aderived supernatants induce proteinuria in the rat following infusion into the renal artery [21] or tail vein [17] . This strategy for investigation of VPF was refined by production of human T cell hybridomas from cells from patients with SSNS [22] . Supernatants from selected hybridomas injected intravenously were shown to produce proteinuria in Wistar rats and reduce the density of polyethylamine staining of glomerular anionic sites.
However, this line of investigation using lymphocytederived VPF has failed to isolate and characterize the bioactive factor despite localization to T cell hybridomas, which can be continuously cultured in large volumes.
Bakker et al. [23, 24] have investigated and characterized a plasma factor (100 KF) from patients with SSNS, which is able to reduce glomerular sialoglycoproteins in vivo and cause proteinuria in rats. This 100 kDa vasoactive factor, which displays kallikreinlike activity, is present in normal human and rat plasma and shows a reduced titre but increased activity in patients in relapse. In vitro, the 100 KF factor is able to modulate the permeability of human endothelial cell monolayers and reduce cell expression of ecto-ATPase anionic sites. In perfusion experiments using rat kidney, the factor reduces the number of anionic sites in the lamina rara interna suggesting the target in vivo is the glomerular endothelium and subendothelial basement membrane. Recently, 100 KF has been characterized as haemopexin, a haeme-binding acute phase reactant [25, 26] .
There are many questions to be answered concerning the in vivo expression and activation of haemopexin in the presence of high levels of 2 -macroglobulin, an effective inhibitor of haemopexin bioactivity. Similarly, it is unclear whether haemopexin induces a selective proteinuria and how it interfaces with the immune system. However, haemopexin is currently the bestdescribed factor isolated from plasma, which could operate as a VPF in SSNS.
Assessment of candidate factors with potential to act as a VPF in SSNS
Our strategy has been to investigate candidate factors for involvement in the pathophysiology of SSNS. A detailed case can be established that two agents, viz. vascular endothelial growth factor (VEGF) and heparanase, have the properties to act as potential VPFs in MCNS. T cell origin T cell origin Con A stimulates production Con A stimulates production Molecular weight 12 kDa Molecular weight 60-160 kDa Induces permeability change in guinea pig skin Induces permeability change in rat kidney Not specific to SSNS PBMCs not cell supernatant affect glomerular charge vi22 P. E. C. Brenchley
Vascular endothelial growth factor
VEGF is a potent, permeability-modulating factor [27] produced in vitro by activated immune cells [28] . In vivo, normal glomerular podocytes are a major source of VEGF and receptors for VEGF are found on glomerular endothelium and mesangial cells [29] .
There is evidence to suggest that the fenestration of glomerular endothelium may be dependent on VEGF, e.g. fenestration of continuous endothelium is induced by VEGF [30, 31] . In vitro, VEGF alters the permeability of endothelial monolayers [32] [33] [34] and in vivo, it has been reported to induce proteinuria in the rat [35] . We have investigated VEGF as a candidate VPF in SSNS [36] . Comparing patients in remission and relapse, we found no differences in PBMC mRNA for VEGF and no differences in either plasma or urinary VEGF levels. Furthermore, in a short-term (4 h) or long-term (3 days) experimental model, we could not induce proteinuria by systemic injection of VEGF. Other workers have failed to demonstrate that VEGF can directly induce proteinuria in a perfused rat kidney model [37] .
We have reported 15 polymorphisms in the VEGF gene [38] and have found no association between the three common polymorphisms and the presentation of nephrotic syndrome (C. J. Watson, N. J. Webb, G. Clark, P. Mathieson and P. E. C. Brenchley, in press).
There remains the possibility that changes in VEGF expression in the kidney occur secondarily to induction of proteinuria as there is evidence of increased VEGF mRNA in a rat model of nephrosis [39] . Likewise, we have shown increased VEGF mRNA by in situ hybridization in biopsies from patients with SSNS [40] . However, current evidence does not support the idea that VEGF is operating as a VPF in SSNS.
Heparanase
We have proposed a hypothesis that over-expression of immune cell-derived heparanase in the vicinity of the GCW is a modulator of heparan sulphate glycosaminoglycan (HSGAG) barrier function in SSNS [41, 42] . Heparanase is an enzyme directly able to modulate the selective permeability of the glomerular capillary wall by its ability to degrade HSGAG, which constitutes the charge barrier. We first described heparanase expression in PBMCs [41] and with the development of a rapid sensitive assay for heparanase; we are currently investigating lymphocyte expression of heparanase as a potential VPF. The recent cloning of the human heparanase gene [43, 44] and demonstration that immune cells, particularly PBMCs, display high levels of constitutive heparanase mRNA suggests an important physiological role of heparanase in immune cell biology. Preliminary studies identify heparanase activity in urine samples from patients with SSNS in relapse (F. Behzad, N. J. Webb, and P. E. C. Brenchley, unpublished observation).
Focal segmental glomerulosclerosis
The evidence for a circulating vasoactive plasma factor in FSGS originates from clinical observation of recurrence of FSGS after renal transplantation [45, 46] . Proteinuria may recur in up to 30% of patients [47] , occasionally within a week. Plasmapheresis [48] and immunoabsorption [49] have been used empirically to reduce proteinuria transiently by removing a circulating factor.
Soulillou's group isolated the FSGS factor on protein A immunosorbent columns and demonstrated that it induced proteinuria in rats by 2.9-4.6-fold compared with the control preparation. The active factor was <100 000 kDa suggesting that it was not simply IgG. Further work using anti-IgG immunoabsorption columns was equally effective in reducing proteinuria and removing the FSGS factor [50] . In vitro analysis of the FSGS factor demonstrated bioactivity in an assay of glomerular albumin permselectivity [51] although the level of factor pre-transplantation was not predictive of recurrence of proteinuria posttransplantation. This group suggests that the FSGS factor is associated with or bound to IgG but that IgG itself is not the pathogenic agent [51] .
Savin et al. [52] have also attempted to characterize the FSGS factor obtained from plasmapheresis samples. Using a bioassay that quantifies the change in glomerular volume in response to an albumin oncotic gradient [53] , they have partially purified the FSGS factor by ammonium sulphate (AS) precipitation. The factor apparently binds to columns of affigel-blue, heparin, protein A and weak anion exchangers but not to con A or cation exchangers [54] . In an analysis of 30 patients with FSGS, only one of 20 patients with no recurrence of disease after transplantation had a permeability activity score greater than 0.5 compared with six of 10 patients who suffered recurrence, P < 0.001. The factor precipitates at 70-80% AS saturation, is heat labile and protease sensitive with an apparent molecular size of 30-50 kDa [52] . Injection of the enriched FSGS factor into rats induces a 3-fold increase in proteinuria between 6 and 24 h after injection. Important questions remain to be answered concerning the role of the 'FSGS factor' ( Table 2) .
Conclusions
This review of VPFs in SSNS has demonstrated that the Shaloub 'lymphokine hypothesis' has been investigated by many groups over the last 25 years but these studies Table 2 . Questions relating to the 'FSGS factor' Important questions relating to the 'FSGS factor' What is its origin and target cell? What is its composition and mechanism of action? What controls over-expression in FSGS? Are there natural antagonists of the factor? VEGF in SSNS and FSGS vi23 have not identified a purified immune-derived factor despite the enormous advances in molecular and cell biology that have occurred over this time (Table 3) . Currently, the only characterized VPF-like factor isolated from plasma is haemopexin and further studies are needed to confirm its role in the pathogenesis of this disease. The apparently strong circumstantial evidence for involvement of the immune system based on control of proteinuria by immunosuppressive drugs may be weakened, if as likely, these agents can be shown to modulate directly podocyte cell biology. Clearly, in some patients with FSGS there is good evidence for VPFs with properties significantly different from those described in SSNS. Progress has been very slow in identifying a purified factor due in part to complex biological assays for permeability. However, the recent discovery of several new genes which encode proteins involved in the structure of the podocyte slit pore diaphragm will provide new targets against which to evaluate the role of VPFs in FSGS.
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